Protagonist Therapeutics
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 28.6m | 27.4m | 26.6m | 60.0m | 285m | 179m | 193m |
% growth | 12293 % | (4 %) | (3 %) | 126 % | 375 % | (37 %) | 8 % |
EBITDA | (63.7m) | (126m) | (131m) | (90.3m) | 191m | (165m) | 193m |
% EBITDA margin | (222 %) | (459 %) | (494 %) | (151 %) | 67 % | (92 %) | 100 % |
Profit | (66.1m) | (126m) | (127m) | (79.0m) | 119m | 7.2m | (16.9m) |
% profit margin | (231 %) | (459 %) | (479 %) | (132 %) | 42 % | 4 % | (9 %) |
EV / revenue | 19.6x | 47.7x | 15.5x | 18.9x | 8.3x | 13.8x | 11.5x |
EV / EBITDA | -8.8x | -10.4x | -3.1x | -12.6x | 12.4x | -15.0x | 11.5x |
R&D budget | 74.5m | 126m | 126m | 120m | - | - | - |
R&D % of revenue | 260 % | 461 % | 475 % | 200 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | $14.0m | Series B | |
* | $4.0m | Series B | |
* | $40.0m | Series C | |
$90.0m | IPO | ||
* | $1.3m | Grant | |
* | $22.0m | Post IPO Equity | |
* | $10.0m | Post IPO Debt | |
* | N/A | $115m | Post IPO Equity |
* | N/A | $132m | Post IPO Equity |
* | N/A | $100m | Post IPO Equity |
Total Funding | €62.1m |
Related Content
Recent News about Protagonist Therapeutics
EditProtagonist Inc. is a clinical-stage biopharmaceutical company that focuses on peptide drug discovery and development. Their mission is to improve patients' lives by addressing areas of unmet need in both rare and prevalent diseases where current treatments are either limited or inadequate. They operate in the healthcare and pharmaceutical market, specifically in the area of drug discovery and development.
Their business model revolves around the discovery, development, and commercialization of peptide-based drugs. They conduct clinical trials to test the efficacy and safety of these drugs, with the ultimate goal of bringing them to market. Once a drug is approved for use, they generate revenue through its sale.
Protagonist Inc. is also committed to health equity and improving access to medicines. They ensure diverse representation in their clinical studies by actively seeking patients from various locations, age groups, and backgrounds. This includes a focus on including aging populations who are often left out of clinical studies.
In addition to their commitment to diverse patient representation, Protagonist Inc. also values diversity and inclusion within their workplace. They believe that a diverse and inclusive corporate culture is critical to their long-term success and innovation.
Keywords: Biopharmaceutical, Peptide Drug Discovery, Clinical Trials, Rare Diseases, Prevalent Diseases, Health Equity, Access to Medicines, Diverse Representation, Inclusion, Workplace Diversity.